Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Gross Margin
Lexicon Pharmaceuticals Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
|
396.1m USD |
99%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
0%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
390.5B USD |
71%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148.1B USD |
70%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
140.9B USD |
79%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
76%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
99B USD |
86%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
96B AUD |
52%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
63.4B USD |
86%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
58.9B USD |
84%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
75%
|
Lexicon Pharmaceuticals Inc
Glance View
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 87 full-time employees. The company went IPO on 2000-04-07. The firm is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes, heart failure and chronic kidney disease. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The firm is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Lexicon Pharmaceuticals Inc's most recent financial statements, the company has Gross Margin of 99.2%.
You don't have any saved screeners yet